Putting Science to Work

Biotherapeutics Discovery

Biotherapeutics have attained a mainstream status in the global drug discovery landscape which has witnessed continuous growth in the recent years. Strength in biotherapeutics discovery and development forms a key differentiator of Syngene.

Syngene’s biotherapeutics discovery service portfolio is further augmented by the inclusion of Antibody Drug Conjugate (ADC) discovery and development capability. Establishment and optimization of conjugation methods, ADC specific analytics and QC, in vitro  and in vivo  functionality assessment, scale up options for linkers, payloads and ADCs are provided to support ADC programs.

This site is best viewed in Firefox (29+), Chrome (35+), or Microsoft Internet Explorer (9+)

FB Side